Clinical Trials Logo

Corticobasal Degeneration (CBD) clinical trials

View clinical trials related to Corticobasal Degeneration (CBD).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03545126 Completed - Clinical trials for Progressive Supranuclear Palsy (PSP)

Human CNS Tau Kinetics in Tauopathies

TANGLES
Start date: August 21, 2017
Phase:
Study type: Observational

The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies.

NCT ID: NCT02365922 Completed - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

ARTFL
Start date: September 2014
Phase:
Study type: Observational

Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes.

NCT ID: NCT02133846 Completed - Clinical trials for Progressive Supranuclear Palsy (PSP)

Safety Study of TPI-287 to Treat CBS and PSP

TPI-287-4RT
Start date: May 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS; also called corticobasal degeneration, CBD) or progressive supranuclear palsy (PSP).